Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
126 hedge funds and large institutions have $199M invested in Lumos Pharma, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 32 increasing their positions, 41 reducing their positions, and 13 closing their positions.
211% more call options, than puts
Call options by funds: $15.2M | Put options by funds: $4.89M
131% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 13
68% more capital invested
Capital invested by funds: $118M → $199M (+$80.7M)
15% more funds holding
Funds holding: 110 → 126 (+16)
22% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$10.6M |
| 2 |
Millennium Management
New York
|
+$9.07M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.89M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$4.32M |
| 5 |
PA
Perceptive Advisors
New York
|
+$3.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$8.65M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$8.03M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$3.26M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.71M |
| 5 |
Renaissance Technologies
New York
|
-$1.58M |
LUMO Hedge Fund Activity: Q3 2017 in Review
126 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q3 2017, worth a combined $199M — up 68% from $118M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new LUMO positions and 13 closed out — a net gain of 17 holders — while 32 added to existing stakes and 41 trimmed.
The largest buyer was Redmile Group, opening a new position worth an estimated $10.6M. The largest seller was OrbiMed, cutting an estimated $8.65M.
- 126 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q3 2017, up from 110 in Q2 2017.
- Funds reported $199M of Lumos Pharma, Inc. Common Stock stock for Q3 2017, up 68% quarter-over-quarter.
- 30 funds opened new Lumos Pharma, Inc. Common Stock positions in Q3 2017 and 13 closed out, a net change of +17 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q3 2017 was Redmile Group, an estimated $10.6M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q3 2017 was OrbiMed, an estimated $8.65M sold.
Based on aggregated 13F filings for Q3 2017.